Recent Emerging Gut Microbiome Management Modalities in Acute Diarrhea in Children: (A Comparative Study Review of Different Probiotic Strains).. An Update

2020 ◽  
Vol 01 (01) ◽  
Author(s):  
Hawal AIM ◽  
Hegab WSM ◽  
El Deib SMM ◽  
Mohamed GI ◽  
Alia MA ◽  
...  
2020 ◽  
Vol 1 (6) ◽  
pp. 01-04
Author(s):  
AMR I.M. Hawal

Aims & Objectives: Acute Diarrhea (AD) is a highly prevalent condition that causes significant morbidity and mortality worldwide. Conventional therapies include oral Rehydration Solutions (ORS), Antibiotics and Zinc Products. Emerging data suggest that Probiotics use in the treatment & control of AD cases in children may help supplement current therapies for further control. Methods Herein, we review the evidence of several Probiotics modalities for AD treatment. We describe the Clinical Impact & prevalence of Acute Diarrhea in children and its complications, provide an overview of current treatments, and finally, discuss recent emergent Gut approaches to AD management. Specifically, we will describe - in a Comparative study - on the utility of different kinds of Probiotics known & used and common natural products in the treatment of Acute cases of AD and focus on recent, high-quality studies. Adverse effects and potential interactions of each therapy will be highlighted where applicable.


2021 ◽  
Vol 160 (6) ◽  
pp. S-566
Author(s):  
Jessica Breton ◽  
Vincent Tu ◽  
Ceylan Tanes ◽  
Maire A. Conrad ◽  
Kelly Kachelries ◽  
...  

F1000Research ◽  
2020 ◽  
Vol 9 ◽  
pp. 46 ◽  
Author(s):  
Eamonn M.M Quigley ◽  
Prianka Gajula

We are in the midst of “the microbiome revolution”—not a day goes by without some new revelation on the potential role of the gut microbiome in some disease or disorder. From an ever-increasing recognition of the many roles of the gut microbiome in health and disease comes the expectation that its modulation could treat or prevent these very same diseases. A variety of interventions could, at least in theory, be employed to alter the composition or functional capacity of the microbiome, ranging from diet to fecal microbiota transplantation (FMT). For some, such as antibiotics, prebiotics, and probiotics, an extensive, albeit far from consistent, literature already exists; for others, such as other dietary supplements and FMT, high-quality clinical studies are still relatively few in number. Not surprisingly, researchers have turned to the microbiome itself as a source for new entities that could be used therapeutically to manipulate the microbiome; for example, some probiotic strains currently in use were sourced from the gastrointestinal tract of healthy humans. From all of the extant studies of interventions targeted at the gut microbiome, a number of important themes have emerged. First, with relatively few exceptions, we are still a long way from a precise definition of the role of the gut microbiome in many of the diseases where a disturbed microbiome has been described—association does not prove causation. Second, while animal models can provide fascinating insights into microbiota–host interactions, they rarely recapitulate the complete human phenotype. Third, studies of several interventions have been difficult to interpret because of variations in study population, test product, and outcome measures, not to mention limitations in study design. The goal of microbiome modulation is a laudable one, but we need to define our targets, refine our interventions, and agree on outcomes.


Author(s):  
O. A. Gromova ◽  
I. Yu. Torshin ◽  
A. G. Chuchalin ◽  
V. A. Maksimov

The gut microbiome is the main source of microorganisms for the formation of microbiomes of other organs and tissues. Dysbiosis of the intestine and lungs associated with COVID-19 leads to an increase in inflammatory reactions and stimulates the development of a cytokine storm through an increase in the activity of toll receptors. The patient’s intestinal dysbiosis facilitates the invasion of coronaviruses and intensifies inflammatory responses. Conversely, the progression of COVID-19 leads to increased dysbiosis in both the lungs and the intestines. Improving the microbiome through probiotic strains of bifido / lactobacilli and prebiotic substances is an important approach to mitigate the “wave” of COVID-19 at the population level.


PLoS ONE ◽  
2020 ◽  
Vol 15 (9) ◽  
pp. e0238764
Author(s):  
Sahar Radwan ◽  
Darby Gilfillan ◽  
Bridget Eklund ◽  
Hend M. Radwan ◽  
Nagwan G. El Menofy ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document